Download PDF
Thromb Haemost 1982; 47(01): 036-040
DOI: 10.1055/s-0038-1657120
Original Article
Schattauer GmbH Stuttgart

Comparative Study of the Activity of High and Low Molecular Weight Urokinase in the Presence of Fibrin

M Samama
1   The Laboratoire Central d'Hématologie, Hôtel-Dieu, Paris, France
,
M Castel
1   The Laboratoire Central d'Hématologie, Hôtel-Dieu, Paris, France
,
O Matsuo
2   The Department of Physiology, Miyazaki Medical College, Miyazaki, Japan
,
M Hoylaerts
3   The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Leuven, Belgium
,
H R Lijnen
3   The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 19 August 1981

Accepted 16 December 1981

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The fibrinolytic or thrombolytic activity of low molecular weight urokinase (LMW-UK) and high molecular weight urokinase (HMW-UK) is not significantly different when measured in a bovine fibrin plate method, in a circulating plasma system containing a 125I-labelled human fibrin clot, or on 125I-fibrin films in culture plates using normal or α2-antiplasmin depleted human plasma.

In a human fibrin plate method however HMW-UK was found to be more active than LMW-UK. In a purified system on human 125I-fibrin films the activation of native or modified human plasminogen by HMW-UK was also found to be more effective than by LMW-UK.

Using a clot lysis test system we did not observe a different inhibition of LMW-UK and HMW-UK upon incubation in human plasma. This is in contrast with previous reports that HMW-UK is inhibited more rapidly in human plasma than LMW-UK.

In a purified system the inhibition rate of LMW-UK and HMW-UK by α2-antiplasmin is the same (rate constants at 25ΰC of 167 ± 9 M−1s−1 and 171 ± 5 M−1s−1 respectively).

The clinical trials available at present used doses of urokinase which were in excess of those required to obtain a maximal fibrinolytic effect. This might explain why in these trials no difference was observed between the thrombolytic effect of LMW-UK and HMW-UK, while in vitro HMW-UK appeared to be more effective. However, one should always be careful to extrapolate in vitro observations as such to the in vivo situation encountered during thrombolytic therapy.

Key words

High and low molecular weight urokinase - Comparison of the fibrinolytic activity - Inhibition in human plasma - Inhibition by α2-antiplasmin
 

  • References

  • 1 Lormeau JC, Goulay J, Vairel EG, Choay J. A comment on the activities of high and low molecular weight urokinase. In: Fibrinolysis. Current Fundamental and Clinical Concepts. Gaffney PJ, Balkuv-Ulutin S. (Eds). 1978: 77-82 Academic Press; London:
    Search in Google Scholar
  • 2 Samama M, Cazenave B, Otero AM. Urokinase I and II activity. Thromb Haemostas 1978; 40: 578-580
    PubMedSearch in Google Scholar
  • 3 Urokinase Pulmonary Embolism Trial. A national cooperative study. American Heart Association Monograph No 39. Circulation 1973; 47: 1-108
    CrossrefPubMedSearch in Google Scholar
  • 4 Urokinase-Streptokinase Pulmonary Embolism Trial. Phase 2, Results. A cooperative study. J Am Med Assoc 1974; 229: 1606-1613
    CrossrefPubMedSearch in Google Scholar
  • 5 Marder VJ, Donahoe JF, Bell WR, Cranley JJ, Kwaan HC, Sasahara AA, Barlow GH. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. J Lab Clin Med 1978; 92: 721-729
    PubMedSearch in Google Scholar
  • 6 Murano G, Aronson DL. High and low molecular weight urokinase. Thromb Haemostas 1979; 42: 1066-1068
    PubMedSearch in Google Scholar
  • 7 Murano G, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-436
    PubMedSearch in Google Scholar
  • 8 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedSearch in Google Scholar
  • 9 Claeys H, Vermylen J. Physicochemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid. Biochim Biophys Acta 1974; 342: 351-359
    CrossrefPubMedSearch in Google Scholar
  • 10 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415-443
    PubMedSearch in Google Scholar
  • 11 Wiman B. Affinity-chromatographic purification of human α2-antiplasmin. Biochem J 1980; 191: 229-232
    CrossrefPubMedSearch in Google Scholar
  • 12 Fenton II JW, Fasco MJ, Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human thrombins. Production, evaluation, and properties of α-thrombin. J Biol Chem 1977; 252: 3587-3598
    PubMedSearch in Google Scholar
  • 13 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
    CrossrefPubMedSearch in Google Scholar
  • 14 Edy J, De Cock F, Collen D. Inhibition of plasmin by normal and antiplasmin depleted human plasma. Thrombos Res 1976; 8: 513-518
    CrossrefPubMedSearch in Google Scholar
  • 15 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
    CrossrefPubMedSearch in Google Scholar
  • 16 Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981; 673: 75-85
    CrossrefPubMedSearch in Google Scholar
  • 17 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
    PubMedSearch in Google Scholar
  • 18 Vermylen C, De Vreker R, Verstraete M. A rapid enzymatic method for assay of fibrinogen: the fibrin polymerization time (FPT-test). Clin Chim Acta 1963; 8: 418-424
    CrossrefPubMedSearch in Google Scholar
  • 19 Friberger P, Knös M. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates. Scully MF, Kakkar VV. (Eds). 128-140 Churchill Livingstone; Edinburgh: 1979
    Search in Google Scholar
  • 20 Suyama T, Nishida M, Iga Y, Naito R. Difference in thrombolytic effect between higher and lower molecular weight forms of urokinase. Thromb Haemostas 1977; 38: 48 (Abstr)
    PubMedSearch in Google Scholar
  • 21 Philo RD, Gaffney PJ. Assay methodology for urokinase: its use in assessing the composition of mixtures of high- and low-molecular weight urokinase. Thromb Res 1981; 21: 81-88
    CrossrefPubMedSearch in Google Scholar
  • 22 Nobuhara M, Sakamaki M, Ohnishi H, Suzuki Y. A comparative study of high molecular weight urokinase and low molecular weight urokinase. J Biochem 1981; 90: 225-232
    CrossrefPubMedSearch in Google Scholar
  • 23 Ogston D, Bennett B, Herbert RJ, Douglas AS. The inhibition of urokinase by α2-macroglobulin. Clin Sci 1973; 44: 73-79
    CrossrefPubMedSearch in Google Scholar
  • 24 Clemmensen I, Christensen F. Inhibition of urokinase by complex formation with human alpha-1-antitrypsin. Biochim Biophys Acta 1976; 429: 591-599
    CrossrefPubMedSearch in Google Scholar
  • 25 Clemmensen I. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin. Thromb Haemostas 1978; 39: 616-623
    PubMedSearch in Google Scholar
  • 26 Moroi M, Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976; 251: 5956-5965
    PubMedSearch in Google Scholar
  • 27 Matsuo O, Kosugi T, Mihara H. Urokinase inactivation rate in the rabbit: effect of circulatory isolation of the liver, spleen and kidneys. Haemostasis 1978; 7: 367-372
    PubMedSearch in Google Scholar
  • 28 Barlow GH, Marder VJ. Determination of plasma urokinase levels by chromogenic assay: comparison of levels attained during infusion of tissue culture and urinary source urokinase preparations. Thromb Haemostas 1979; 42: 295 (Abstr)
    PubMedSearch in Google Scholar
  • 29 Barlow GH, Francis CW, Marder VJ. On the conversion of high molecular weight urokinase to the low molecular weight form. Thromb Haemostas 1981; 46: 11 (Abstr)
    PubMedSearch in Google Scholar